The purpose of this study was to investigate the association between chronic kidney disease (CKD) and peripheral arterial disease (PAD) and examine the combined effect of CKD and PAD on all-cause and cardiovascular disease (CVD) mortality. The Chinese Ankle Brachial Index Cohort consisted of 3732 adults aged 35 years or older enrolled in 2004 and followed-up in 2007. Complete baseline data were compiled on 3610 people which were examined in the final analysis. Mortality surveillance was completed from December 2007 to February 2008. Survival analysis was used to compare the survival rate in different CKD/PAD groups. The relative risks (RR) of death from all-cause and CVD were compared using a Cox regression model. It was found that the prevalence of PAD in patients with and without CKD was 41.9% and 22.3%, respectively (p < 0.001). The survival rate for the CKD and PAD group was significantly lower than that for any single disease, for both all-cause and CVD mortality (log-rank: p < 0.001). In conclusion, CKD is a risk factor for PAD. The combined CKD and PAD patients had the highest risk for all-cause and CVD mortality. Early recognition of risk can be made by taking an ankle-brachial index measurement of PAD; a corresponding laboratory assessment should be used as a measurement of renal function for PAD patients.
Introduction
Peripheral arterial disease (PAD) is a common disease with a prevalence rate of 14.5% among those aged ≥ 70 years in the United States and in 16.7% of Chinese patients with type 2 diabetes. 1, 2 Many studies have shown that PAD is a major predictor of all-cause and cardiovascular disease (CVD) mortality. [3] [4] [5] [6] [7] However, only a small percentage of these individuals with PAD are symptomatic; PAD is poorly recognized in the primary care setting. 8, 9 Chronic kidney disease (CKD) is also highly prevalent in the general population, especially in patients with cardiovascular risk factors. 10, 11 According to recent reports, even mild to moderate CKD is a powerful independent predictor of all-cause and CVD mortality. 12, 13 As with PAD, patients with CKD often receive inadequate treatment because of the low awareness and testing for CKD. 14, 15 Since CKD and PAD share many risk factors, it is not surprising that the prevalence of PAD is especially high in patients with CKD. Estimates from the Third National Health and Nutrition Examination Survey (NHANES III) showed that the prevalence of PAD is 24% in patients with CKD. 16 Moreover, both PAD and CKD will result in a high risk of all-cause and CVD mortality. [3] [4] [5] [6] [7] 12, 13 However, few studies have examined the mortality of PAD in patients with CKD. The combined effect of CKD and PAD on all-cause and CVD mortality among Asians has not been reported. Thus, the purposes of this study were to investigate the association between CKD and PAD and to examine the risk of all-cause and CVD mortality for individuals with both PAD and CKD, PAD alone and CKD alone, compared with individuals without PAD and CKD.
Materials and methods

Study subjects
The Chinese Ankle Brachial Index Cohort Study was designed in 2004 to investigate the risk factors of PAD and to examine the relationship between the ankle-brachial index (ABI) and mortality from all-cause and CVD. Subjects were recruited from in-patient clinics at the departments of endocrinology or cardiology at eight university affiliated hospitals in Beijing and Shanghai from July to November 2004. A total of 3732 patients aged 35 years or older were recruited into the cohort. For this investigation, we excluded 23 participants without serum creatinine data, 12 participants who had possible medial arterial calcifi cation (MAC), defined by an ABI > 1.4, and 87 participants who had end-stage renal disease (ESRD), defined by an estimated glomerular filtration rate (eGFR) < 15 ml/min per 1.73 m 2 or dialysis treatment, leaving a total of 3610 participants, including 1914 (53%) men and 1696 (47%) women for the final analysis.
Patients were categorized according to their CKD and PAD status into four groups: CKD and PAD (eGFR < 60 ml/min per 1.73 m 2 + ABI ≤ 0.9); PAD alone (eGFR ≥ 60 ml/min per 1.73 m 2 + ABI ≤ 0.9); CKD alone (eGFR < 60 ml/min per 1.73 m 2 + ABI > 0.9); or no CKD and PAD (eGFR ≥ 60 ml/min per 1.73 m 2 + ABI > 0.9). The followup visit was between December 2007 and February 2008; 3109 participants had complete follow-up data. Patients who were lost to follow-up were treated as censored in the Cox model. There were 40 (13.9%), 105 (16.1%), 47 (11.8%), and 309 (13.6%) patients censored in the CKD and PAD group, PAD alone group, CKD alone group and no CKD or PAD group, respectively (p = 0.226). This study was approved by the ethics committee of Tongji University and informed consent was obtained from each participant.
Measurement of ankle and arm blood pressures
Doppler ultrasound (Elite 100R; Nicolet Vascular, USA) was used to measure systolic pressure on the bilateral brachial, position tibial and dorsal pedal arteries in the supine position after a 5-min rest. The occluding cuffs (55 × 12.5 cm) were applied just above the malleoli to measure ankle pressure. The Doppler probe was used at a frequency of 5 MHz. Right and left ABI were calculated by the highest pressure on the dorsal or posterior tibial arteries on the right and left sides, respectively, and by the highest brachial pressure on either side. Of the two ABI measurements for each patient, we selected the lowest ABI for study use.
Diagnosis of PAD
Early studies used an ABI cut-off point of < 0.90 to define PAD. 17 More recently, the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines have recommended an ABI ≤ 0.90 as the criterion for diagnosis of PAD. 18 Thus, our study adopted this recommendation for participants with an ABI ≤ 0.90 in either leg as PAD. On the other hand, participants with an ABI from 0.91 to 1.40 were considered without PAD.
Ascertainment of the level of kidney function
Kidney function was ascertained by eGFR, which was calculated using the formula that was developed and validated in the Modification of Diet in Renal Disease (MDRD) study. 19 This formula is also validated in the Chinese population. 20 The MDRD formula is as follows:
Thus, the eGFR was categorized into eGFR ≥ 60 ml/min per 1.73 m 2 (no CKD), 45-59.9 ml/min per 1.73 m 2 (mild CKD), 30-44.9 ml/min per 1.73 m 2 (moderate CKD) and 15-29.9 ml/min per 1.73 m 2 (severe CKD). Patients with eGFR < 15 ml/min per 1.73 m 2 were excluded.
Identification of all-cause and CVD mortality
Death was confirmed from hospital records or by contact with participants' family members. Cause of death was investigated using medical records and interviews. All materials were reviewed independently by a physician of the ABI Cohort Study to confirm the cause of death.
Statistical analysis
Data were analyzed using the software program SPSS 13.0. Continuous variables were expressed as the mean ± SD, and categorical variables as n (%). Independent-samples t-test or ANOVA, and the chi-squared test were used to compare continuous and categorical variable differences among groups. A p-value < 0.05 was considered statistically significant. Cumulative mortality rates from all-cause and CVD were computed among different groups. Survival analysis based on Kaplan-Meier curves and log-rank tests were used to compare survival rates in different PAD/CKD groups. The relative risks of death from all-cause and CVD were adjusted for potential confounders, including age, sex, diabetes, hypertension, stroke, coronary heart disease (confirmed by coronariangiography, a previous myocardial infarction, or surgery or coronary revascularization), and smoking, using a Cox regression model.
Results
Of 3610 entered into the cohort, there were 38.6% of patients with diabetes, 72.4% with hypertension, 42.6% had a history of stroke, 55.4% had a history of chronic heart disease (confirmed by coronariangiography, a previous myocardial infarction, or surgery or coronary revascularization), and 39.3% were smokers; as shown in Table 1 . Nine hundred thirty-eight participants (26.0%) were in the low-ABI group, which was diagnosed with PAD, and the remainder was in the normal-ABI group. The prevalence of PAD was 26.0% in the cohort. During a mean follow-up of 37.64 ± 1.54 months, 501 (13.9%) of them were lost during the follow-up because of changing telephone number and mailing address. There is no significant difference in CKD prevalence and PAD prevalence among subjects with and without follow-up data. Thus, among the 3109 participants who have complete follow-up data, 471 of them died, 278 (59%) attributed to CVD. The 3-year cumulative all-cause and CVD mortality rate was 15.1% and 8.9%, respectively. The cause of death is shown in Table 2 .
Comparison of baseline characteristics among four groups
We found that patients with combined CKD and PAD were more likely to be older, with higher systolic blood pressure, a higher triglyceride level, higher fasting plasma glucose, lower HDL cholesterol and have more diabetes, hypertension, and history of stroke and coronary heart disease than those with a single disease and those without CKD and PAD, as shown in Table 1 .
Relationship of CKD and PAD
The prevalence of PAD in patients with and without CKD was 41.9% and 22.3%, respectively (p < 0.001). After adjustment for traditional CVD risk factors such as age, sex, hypertension, diabetes, hypercholesterolemia and smoking history, CKD associated with PAD with the relative risk (RR) of 1.84 (95% CI: 1.50-2.27). When the level of kidney function was classified into four groups by eGFR, the prevalence of PAD was 48.7% (95% CI: 37.6-59.8%), 48.5% (95% CI: 41.0-56.0%), 38.1% (95% CI: 33.6-42.7%), and 22.3% (95% CI: 20.8-23.8%) in each CKD group, as shown in Figure 1 . The 3-year mortality rates were 36.2%, 32.2%, 23.0%, and 12.4% in the severe CKD group, moderate CKD group, mild CKD group and no CKD group, respectively (p < 0.001). Figure 2 shows the all-cause and CVD mortality in different CKD/PAD groups. Of 3109 participants with complete follow-up data, they were classified into four groups: 287 in the CKD and PAD group, 651 in the PAD alone group, 398 in the CKD alone group, and 2274 in the no CKD and PAD group. The all-cause mortality was 38.5%, 19.0%, 18.5%, and 10.5%, respectively, and CVD mortality was 23.5%, 12.5%, 12.0%, and 5.6%, with a significant difference between each other (p < 0.001). 
All-cause and CVD mortality in different CKD/PAD groups
Survival analysis for different CKD/PAD groups
Kaplan-Meier curves in Figure 3A and B show the survival distribution of the four groups for all-cause and CVD mortality, respectively. The survival rate for the CKD and PAD group was significantly lower than that for single disease or the without CKD or PAD group, for both all-cause and CVD mortality (log-rank: p < 0.001). Figure 4A 
Mortality risks according to different CKD/PAD groups
Discussion
Few studies have examined the relationship between CKD and PAD and the risk of all-cause and CVD mortality for individuals with CKD and PAD, especially in the Chinese population. One recent study 21 reported that moderate to severe CKD was strongly associated with 1-year mortality, independent of traditional CVD risk factors. However, that study was limited by its short follow-up year and the PAD population contained only those with advanced PAD (rest pain, ischemic ulceration or gangrene). Another study 22 showed that patients with both CKD and PAD have a significantly higher risk of death than patients with either disease alone. However, the participants were primarily Caucasians and the data came from the vascular laboratory.
In addition, the study had significant selection bias, and neither of these studies involved CVD mortality. In our study, patients with combined CKD and PAD were more likely to be older, and have more diabetes, hypertension, history of stroke and history of CHD. It is possible that CKD and PAD have some common risk factors. The prevalence of PAD is much higher in patients with CKD than in those without CKD (41.9% vs 22.3%, p < 0.001).
To assess the risk of PAD according to kidney function, the level of kidney function was classified into four groups by eGFR. The prevalence of PAD increased as the eGFR decreased. Since CKD accelerate atherogenesis 23 and PAD is a clinical manifestation of the atherosclerotic process, CKD and PAD share many risk factors. It is not surprising that the prevalence of PAD is significantly higher in patients with CKD, especially in severe and moderate CKD. However, CKD remains strongly associated with PAD even after adjustment for traditional CVD risk factors, with the adjusted RR of 1.842 (95%CI: 1.495-2.268). This is similar to previous reports where the adjusted RRs ranged from 1.4 to 2.5. 16, [24] [25] [26] Therefore, the traditional CVD risk factors are unlikely to explain the high prevalence of PAD in CKD subjects completely.
In the present study, participants in the combined CKD and PAD group had the lowest survival rate from survival analysis based on Kaplan-Meier curves. The adjusted RRs from all-cause and CVD mortality were more than three times that of the neither CKD or PAD group, and also higher than the CKD alone and PAD alone groups. That means if an individual has CKD and at the same time has PAD, he/she will be at the highest risk of death, especially death from CVD. It is possible that CKD promotes hypertension and dyslipidemia, which accelerate the atherosclerotic process and progression of PAD. It is also possible that CKD will result in PAD, and then increased the mortality, or there is a combined effect of CKD and PAD to all-cause and CVD mortality. There may be additional, unknown mechanisms involved in both diseases that may compound accelerated progression of one or the other over time. These two diseases may share not only traditional CVD risk factors but also non-traditional risk factors, such as increased inflammatory markers and hyper-homocysteinemia, which may have contributed to accelerated atherosclerosis. [27] [28] [29] [30] A total of 41.9% of CKD patients had PAD and the patients who had CKD at the same time had the highest all-cause and CVD mortality; therefore, PAD screening in CKD patients should be encouraged for the goal of secondary prevention. Early detection and early diagnosis of PAD in CKD patients may help combined PAD/CKD patients recognize their PAD status, prevent other atherosclerotic risk factors and then reduce the high mortality rate.
In conclusion, our study analyzed the relationship between CKD and PAD and the risk of all-cause and CVD mortality for individuals with PAD, CKD, and both conditions relative to that for individuals with neither condition. We found that CKD is a risk factor for PAD and the patients with combined CKD and PAD had the highest risk for all-cause and CVD mortality. Since ABI and eGFR are two sensitive, non-invasive and inexpensive measurement tools for disease definition and detection, our suggestion is that CKD patients should undertake an ABI measurement for PAD early recognition and eGFR should be used as a measurement of renal function in PAD patents for the goal of secondary prevention.
Potential limitations of our study include the relatively brief duration of follow-up and the inclusion of subjects in a high-risk population. Other limitations include the single measurement of serum creatinine for eGFR calculation, no assessment of microalbuminuria, and a lack of various nontraditional risk factors available for analysis. The pathophysiological mechanisms by which PAD combined with CKD result in all-cause and CVD mortality should be paid attention in further investigations.
